14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
COCP vs AIM: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Cocrystal Pharma, Inc. (COCP) is the stronger overall head-to-head candidate over AIM ImmunoTech Inc. (AIM) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). COCP carries a Unified Composite Score of 47.1/100 (HOLD) at $1.00 (N/M Forward P/E, -3063.6% operating margin), whereas AIM carries 52.8/100 (HOLD) at $0.13 (2.0x Forward P/E, -11724.2% operating margin).
Composite vs. Pillar Nuance: While AIM currently prints a higher short-term Unified Composite Score (52.8/100 HOLD vs. COCP 47.1/100 HOLD), COCP captures the overall institutional head-to-head verdict (6–3 matrix metrics and 3–1 across the 6 pillars) due to superior fundamental profitability (-3063.6% vs. -11724.2% operating margin) and revenue trajectory (+26.9% vs. +4.0% YoY).
Technical & Structure Timing Caution: COCP trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 46.3); meanwhile AIM is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Competes within the Biotechnology value chain with $5.9M market capitalization and -11724.2% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ COCP vs AIM Key Questions & Quantitative Answers
As of Nov 16, 2026, Cocrystal Pharma, Inc. (COCP) is the stronger overall head-to-head candidate over AIM ImmunoTech Inc. (AIM) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). COCP carries a Unified Composite Score of 47.1/100 (HOLD) at $1.00 (N/M Forward P/E, -3063.6% operating margin), whereas AIM carries 52.8/100 (HOLD) at $0.13 (2.0x Forward P/E, -11724.2% operating margin). Composite vs. Pillar Nuance: While AIM currently prints a higher short-term Unified Composite Score (52.8/100 HOLD vs. COCP 47.1/100 HOLD), COCP captures the overall institutional head-to-head verdict (6–3 matrix metrics and 3–1 across the 6 pillars) due to superior fundamental profitability (-3063.6% vs. -11724.2% operating margin) and revenue trajectory (+26.9% vs. +4.0% YoY). Technical & Structure Timing Caution: COCP trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 46.3); meanwhile AIM is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
COCP leads the Growth & Scale pillar: COCP posts +26.9% YoY revenue growth and +0.0% YoY earnings growth on $330,000 TTM revenue (N/A gross margin, -3063.6% operating margin), compared with AIM at +4.0% YoY revenue growth and +0.0% YoY earnings growth on $95,000 TTM revenue (-23.2% gross margin, -11724.2% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), COCP cumulative revenue shifted N/A while AIM shifted N/A. In operating R&D and SG&A reinvestment, COCP deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for AIM.
AIM screens cheaper on headline valuation multiples. COCP trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 49.7x EV/Revenue (unreported FCF margin), whereas AIM trades at 2.0x Forward P/E, 2.0x Trailing P/E, 0.71x PEG, and 62.4x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against COCP (-311.7% ROE) versus AIM (-2382.3% ROE) capital efficiency.
In options market volatility and institutional positioning, COCP carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.04β · 54% Vol realized risk). By comparison, AIM carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.32β · 69% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.